China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the commencement of a Phase I clinical study for GPN00884, an innovative ophthalmic drug aimed at arresting the progression of childhood myopia, with the first patient now dosed. This randomized, double-blind, placebo-controlled, dose-escalation study is designed to evaluate the safety, tolerability, and pharmacokinetic profile of GPN00884 in healthy subjects, with an anticipated enrollment of 40 participants.
GPN00884 stands out against low-concentration atropine eye drops, as it does not cause pupil dilation and is devoid of adverse reactions such as photophobia or impaired accommodation. The lack of restrictions on the administration period is expected to enhance patient compliance. Currently, there is a significant gap in the Chinese market for drugs that have proven efficacy and safety in delaying the progression of myopia in children, indicating an unmet clinical need. GPN00884 is poised to offer healthcare providers and patients a novel clinical treatment option aimed at curbing the advancement of myopia in pediatric patients.- Flcube.com
